|
|
Found results for
 patents
1.
|
Pharmaceutical composition comprising meta arsenite and method of manufacture
| Application Number |
16982399 |
| Grant Number |
12257347 |
| Status |
In Force |
| Filing Date |
2019-03-21 |
| First Publication Date |
2021-01-07 |
| Grant Date |
2025-03-25 |
| Owner |
- Komipharm International Australia Pty Ltd (Australia)
- PANAPHIX INC. (USA)
|
| Inventor |
Yang, Yong-Jin
|
Abstract
The present application relates to pharmaceutical compositions comprising a salt of arsenous acid, such as sodium meta arsenite or potassium meta arsenite, and methods of manufacturing the pharmaceutical compositions.
IPC Classes ?
- A61K 9/20 - Pills, lozenges or tablets
- A61K 9/00 - Medicinal preparations characterised by special physical form
- A61K 9/28 - DrageesCoated pills or tablets
- A61K 33/36 - ArsenicCompounds thereof
|
2.
|
PHARMACEUTICAL COMPOSITION COMPRISING META ARSENITE AND METHOD OF MANUFACTURE
| Application Number |
AU2019050249 |
| Publication Number |
2019/178643 |
| Status |
In Force |
| Filing Date |
2019-03-21 |
| Publication Date |
2019-09-26 |
| Owner |
- KOMIPHARM INTERNATIONAL AUSTRALIA PTY LTD (Australia)
- PANAPHIX INC. (USA)
|
| Inventor |
Yang, Yong-Jin
|
Abstract
The present application relates to pharmaceutical compositions comprising a salt of arsenous acid, such as sodium meta arsenite or potassium meta arsenite, and methods of manufacturing the pharmaceutical compositions..
|
3.
|
Use of arsenic compounds for treatment of pain and inflammation
| Application Number |
13869911 |
| Grant Number |
10058570 |
| Status |
In Force |
| Filing Date |
2013-04-24 |
| First Publication Date |
2013-11-21 |
| Grant Date |
2018-08-28 |
| Owner |
Panaphix Inc. (USA)
|
| Inventor |
- Hwang, Michael
- Yang, Yong Jin
|
Abstract
6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
IPC Classes ?
- A61K 33/36 - ArsenicCompounds thereof
- A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
|
4.
|
Use of arsenic compounds for treatment of pain and inflammation
| Application Number |
12068006 |
| Grant Number |
08945505 |
| Status |
In Force |
| Filing Date |
2008-01-31 |
| First Publication Date |
2008-08-14 |
| Grant Date |
2015-02-03 |
| Owner |
Panaphix, Inc. (USA)
|
| Inventor |
Yang, Yong Jin
|
Abstract
6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
IPC Classes ?
- C01G 28/02 - ArsenatesArsenites
- A61K 33/36 - ArsenicCompounds thereof
- A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
|
5.
|
USE OF ARSENIC COMPOUNDS FOR TREATMENT OF PAIN AND INFLAMMATION
| Application Number |
US2008052751 |
| Publication Number |
2008/097824 |
| Status |
In Force |
| Filing Date |
2008-02-01 |
| Publication Date |
2008-08-14 |
| Owner |
PANAPHIX INC. (USA)
|
| Inventor |
- Hwang, Michael
- Yang, Yong-Jin
|
Abstract
The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (AS2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
IPC Classes ?
- A61K 33/36 - ArsenicCompounds thereof
- A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
|
|
